Showing results (41-50 of 279) with videos related to
Sort By:
Pageof 28
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2022
Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE TrialMatthias Stelljes, Anjali S Advani, Daniel J DeAngelo, et al.British Journal of Haematology|March 21, 2022
Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemiaYannis K Valtis, Andrew E Place, Lewis B Silverman, et al.Journal of Clinical Pathology|March 29, 2018
Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary diseaseAlissa Keegan, Karry Charest, Ryan Schmidt, et al.Clinical Lymphoma, Myeloma & Leukemia|August 6, 2011
Candida albicans cervical lymphadenitis in patients who have acute myeloid leukemiaMarcella M Alsan, Nicolas C Issa, Sarah P Hammond, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 16, 2015
Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemiaOlga K Weinberg, Olga Pozdnyakova, Federico Campigotto, et al.Journal of Oncology Practice|August 15, 2013
Impact of physician assistants on the outcomes of patients with acute myelogenous leukemia receiving chemotherapy in an academic medical centerBrett E Glotzbecker, Deborah S Yolin-Raley, Daniel J DeAngelo, et al.Blood Reviews|February 22, 2023
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDSStacey M Frumm, Shai Shimony, Richard M Stone, et al.Journal of Hematology & Oncology|December 28, 2018
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel reviewJorge E Cortes, Jane F Apperley, Daniel J DeAngelo, et al.Current Medical Research and Opinion|October 31, 2014
One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparisonJames E Signorovitch, Keith A Betts, William M Reichmann, et al.Journal of Thrombosis and Haemostasis : JTH|January 31, 2020
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTHJeffrey I Zwicker, Tzu-Fei Wang, Daniel J DeAngelo, et al.Pageof 28